Combining radiotherapy and angiogenesis inhibitors: Clinical trial design
D. Citrin, C. Menard, and K. Camphausen Combining radiotherapy and angiogenesis inhibitors: clinical trial design Int J Radiat Oncol Biol Phys 64 2006 15 25
Irradiation combined with SU5416: Microvascular changes and growth delay in a human xenograft glioblastoma tumor line
J. Schuuring, J. Bussink, and H.J. Bernsen Irradiation combined with SU5416: microvascular changes and growth delay in a human xenograft glioblastoma tumor line Int J Radiat Oncol Biol Phys 61 2005 529 534
The functional diffusion map: An imaging biomarker for the early prediction of cancer treatment outcome
B.A. Moffat, T.L. Chenevert, and C.R. Meyer The functional diffusion map: an imaging biomarker for the early prediction of cancer treatment outcome Neoplasia 8 2006 259 267
Monitoring early response of experimental brain tumors to therapy using diffusion magnetic resonance imaging
T.L. Chenevert, P.E. McKeever, and B.D. Ross Monitoring early response of experimental brain tumors to therapy using diffusion magnetic resonance imaging Clin Cancer Res 3 1997 1457 1466
Dynamic contrast-enhanced magnetic resonance imaging of vascular changes induced by sunitinib in papillary renal cell carcinoma xenograft tumors
G.G. Hillman, V. Singh-Gupta, and H. Zhang Dynamic contrast-enhanced magnetic resonance imaging of vascular changes induced by sunitinib in papillary renal cell carcinoma xenograft tumors Neoplasia 11 2009 910 920
Examining the acute effects of cediranib (RECENTIN, AZD2171) treatment in tumor models: A dynamic contrast-enhanced MRI study using gadopentate
D.P. Bradley, J.J. Tessier, and T. Lacey Examining the acute effects of cediranib (RECENTIN, AZD2171) treatment in tumor models: a dynamic contrast-enhanced MRI study using gadopentate Magn Reson Imaging 27 2009 377 384
Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer
S. Faivre, C. Delbaldo, and K. Vera Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer J Clin Oncol 24 2006 25 35
New model of tumor angiogenesis: Dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF
J. Holash, S.J. Wiegand, and G.D. Yancopoulos New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF Oncogene 18 1999 5356 5362
Three-dimensional micro-MRI analysis of cerebral artery development in mouse embryos
C.A. Berrios-Otero, Y.Z. Wadghiri, and B.J. Nieman Three-dimensional micro-MRI analysis of cerebral artery development in mouse embryos Magn Reson Med 62 2009 1431 1439
Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastoma
S. de Bouard, P. Herlin, and J.G. Christensen Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastoma Neuro Oncol 9 2007 412 423
ADC response to radiation therapy correlates with induced changes in radiosensitivity
M.P. Larocque, A. Syme, and J. Allalunis-Turner ADC response to radiation therapy correlates with induced changes in radiosensitivity Med Phys 37 2010 3855 3861
Temporal and dose dependence of T2 and ADC at 9.4 T in a mouse model following single fraction radiation therapy
M.P. Larocque, A. Syme, and A. Yahya Temporal and dose dependence of T2 and ADC at 9.4 T in a mouse model following single fraction radiation therapy Med Phys 36 2009 2948 2954
Monitoring T2 and ADC at 9.4 T following fractionated external beam radiation therapy in a mouse model
M.P. Larocque, A. Syme, and A. Yahya Monitoring T2 and ADC at 9.4 T following fractionated external beam radiation therapy in a mouse model Phys Med Biol 55 2010 1381 1393